Alnylam Pharmaceuticals (ALNY) Net Cash Flow Growth (5y) (2014 - 2026)
Alnylam Pharmaceuticals (ALNY) Net Cash Flow Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.46% |
| Dec 31, 2025 | 125.04% |
| Sep 30, 2025 | 44.87% |
| Jun 30, 2025 | -10.08% |
| Mar 31, 2025 | 20.14% |
| Dec 31, 2024 | 20.90% |
| Sep 30, 2024 | 20.54% |
| Jun 30, 2024 | -6.80% |
| Mar 31, 2024 | -19.08% |
| Dec 31, 2023 | -33.41% |
| Sep 30, 2023 | 60.20% |
| Jun 30, 2023 | 16.14% |
| Mar 31, 2023 | 4.64% |
| Dec 31, 2022 | -19.82% |
| Sep 30, 2022 | 34.48% |
| Jun 30, 2022 | -26.69% |
| Mar 31, 2022 | -65.95% |
| Dec 31, 2021 | -66.49% |
| Sep 30, 2021 | 40.25% |
| Jun 30, 2021 | 55.77% |